Jenny Barba

Laplace Interventional is developing a minimally invasive transcatheter treatment for patients suffering from Tricuspid Regurgitation.

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. In addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications. OCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.

Laplace Interventional is developing a minimally invasive transcatheter treatment for patients suffering from Tricuspid Regurgitation.

Private Equity Women Investor Network (PEWIN) is an organization that provides an intimate forum for senior women general partners, limited partners and private equity professionals to network, share investment ideas, explore potential opportunities to work together and generally increase the profile of female leaders in our industry. Founded in 2008, this invitation-only group currently has over 1500 members globally at the most senior levels of their respective firms. PEWIN has also become a natural network for its many women CIOs and hosts several high profile CIO Roundtable events throughout the year in various locations where our members gain unprecedented access to this elite group of leaders in the industry.

Features Capital is a 100% diverse led venture capital firm specializing in medical technology investing. We partner with visionary LPs to invest in brilliant founders and early-stage healthcare innovation. Founded by Jenny Barba and Jeff Chu, our collective 45+ years of experience as operators, investors, and advisors of MedTech companies enhances our support alongside driven management teams to build and scale. Our platform of investments improves patient outcomes, increase access to care, create efficiencies, improve health equity, and reduce costs while solving unmet needs to win in billion-dollar markets.

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. In addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications. OCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.

ADVANCING THE GROWTH OF MEDTECH: We are partner with the innovators who are changing the practice of medicine. BioVentures MedTech Funds invests in companies that are developing today’s leading-edge biomedical technologies. Together, we create dynamic solutions that improve health outcomes and reduce the cost of care.